<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It has been reported that <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi> FK506 inhibited ischemic neuronal injury in forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> or transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, but the mechanisms of the neuroprotective effect have not been clarified </plain></SENT>
<SENT sid="1" pm="."><plain>In permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, we investigated whether FK506 caused remission of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e>, and how mechanism was concerned </plain></SENT>
<SENT sid="2" pm="."><plain>Male Balb/c mice were subjected to permanent middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion </plain></SENT>
<SENT sid="3" pm="."><plain>They were treated with 1.0 or 3.0 mg/kg FK506 or vehicle 30 min before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was assessed by 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> (TTC) method after 24 h </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="1" ids="18070">Cytochrome c</z:chebi> release from mitochondria was evaluated by Western blotting and immunocytochemistry after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Simultaneously, the immunoreactivity of total and phosphorylated BAD was also studied using immunocytochemistry </plain></SENT>
<SENT sid="7" pm="."><plain>We demonstrated that pretreatment with 3.0 mg/kg FK506 salvaged the tissue damage in the <z:mpath ids='MPATH_124'>infarct</z:mpath> rim and significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume to 75.5% (P&lt;0.05), and FK506 inhibited <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> release on 6 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> for Western blot analysis (P&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Immunocytochemical study showed that permanent <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion increased the amount of <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> and total BAD in the cytosol, but not phosphorylated BAD, in the ischemic core and the <z:mpath ids='MPATH_124'>infarct</z:mpath> rim as early as 1 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, and FK506 inhibited the increases in the <z:mpath ids='MPATH_124'>infarct</z:mpath> rim </plain></SENT>
<SENT sid="9" pm="."><plain>The results suggest that FK506 may, at least in part, ameliorate tissue damage due to permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in the <z:mpath ids='MPATH_124'>infarct</z:mpath> rim through maintaining BAD turnover and inhibiting <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> release from mitochondria </plain></SENT>
</text></document>